The use of ICIs—monoclonal antibodies targeting programmed death protein 1 (PD-1), programmed death protein 1 ligand (PD-L1) and CTLA-4—has yielded impressive results in many settings and is currently a cornerstone in cancer treatment, including BC (54). Here, CD274 is linked to breast cancer.